Expanding the reach of antibody therapeutics
Determined to revolutionize the reach of cancer treatment by developing potent and precise therapies that can target the entire universe of cancer antigens
Why Crossbow
We aim to cure cancer. Our team is urgently working to create an arsenal of therapeutics that expands the reach and impact of antibodies used to treat cancer.
We chose the name Crossbow because our next-generation therapies embody the precision and power of a crossbow. With unparalleled accuracy and potency, our T-Bolt molecules strike tumor cells like a crossbow shoots bolts at its target.
Join us on our bold quest to broaden the benefits of immunotherapy and improve the lives of people living with cancer.
TM
What we do
Selecting from the expanding universe of cancer antigens
We identify, validate and prioritize the most promising cancer antigens for our T-Cell Receptor Mimetic (TCRm) discovery efforts.
Who we are
A team of international, collaborative and experienced inventors, drug developers and company builders. We value scientific excellence, passion, integrity, innovation, transparency, respect and accountability. We embrace problems deemed impossible to solve.
Briggs
Morrison, M.D.
Chief Executive Officer, President
Michael
Princiotta, Ph.D.
Senior Vice President of Biology
Benjamin Lee,
M.D., Ph.D.
Senior Vice President, Translational Medicine
Dmitri
Wiederschain, Ph.D.
Chief Scientific Officer
Amanda
Mak, Ph.D.
Vice President of Antibody Discovery, Protein Engineering, Process Development
Jeanne
Freddura, M.S.
Vice President of Finance
Geraldine
Paulus, Ph.D.
Co-founder, Vice President of Corporate Development and Operations
Tao
Wang, M.S.
Vice President of Product Discovery, Boston Site Head
Jeanette
Kohlbrenner, M.B.A.
Consulting Head of Human Resources
News & Media
Keep up to date with everything happening at Crossbow
July 11, 2023
Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance
a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer
